JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB259016

Human OASL knockout A549 cell lysate

Be the first to review this product! Submit a review

|

(0 Publication)

OASL KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon2 and 1 bp insertion in exon2 and 4 bp deletion in exon2.

View Alternative Names

2''-5''-OAS-RP, 2''-5''-OAS-related protein, 2''-5''-oligoadenylate synthase-like protein, 2'-5' oligoadenylate synthetase-like 2, 2'-5'-oligoadenylate synthetase-like, 59 kDa 2'-5'-oligoadenylate synthetase-like protein, Mmu-OASL, OASL_HUMAN, Oasl2, THYROID HORMONE RECEPTOR INTERACTOR 14, TR-interacting protein 14, TRIP-14, Thyroid receptor-interacting protein 14, p59 OASL

3 Images
Sanger Sequencing - Human OASL knockout A549 cell lysate (AB259016)
  • Sanger seq

Unknown

Sanger Sequencing - Human OASL knockout A549 cell lysate (AB259016)

Allele-3 : 1 bp insertion in exon2

Sanger Sequencing - Human OASL knockout A549 cell lysate (AB259016)
  • Sanger seq

Unknown

Sanger Sequencing - Human OASL knockout A549 cell lysate (AB259016)

Allele-1 : 4 bp deletion in exon2

Sanger Sequencing - Human OASL knockout A549 cell lysate (AB259016)
  • Sanger seq

Unknown

Sanger Sequencing - Human OASL knockout A549 cell lysate (AB259016)

Allele-2 : 1 bp deletion in exon2

Key facts

Cell type

A549

Species or organism

Human

Tissue

Lung

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon2 and 1 bp insertion in exon2 and 4 bp deletion in exon2.

Disease

Carcinoma

Product details

Knockout cell lysate achieved by CRISPR/Cas9.

REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.

User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1Kit": { "sellingSize": "1 Kit", "publicAssetCode":"ab259016-1Kit", "assetComponentDetails": [ { "size":"1 x 100 µg", "name":"Human OASL knockout A549 cell lysate", "number":"AB259016-CMP02", "productcode":"" }, { "size":"1 x 100 µg", "name":"Human wild-type A549 cell lysate", "number":"AB259016-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
OASL
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

OASL also known as 2'-5'-oligoadenylate synthetase-like protein functions mechanically by enhancing antiviral defense mechanisms. This protein weighs approximately 58 kDa and is expressed in various cell types including immune cells such as monocytes and lymphocytes. OASL belongs to the family of interferon-stimulated genes and shares structural similarities with other 2'-5'-oligoadenylate synthetases.
Biological function summary

OASL plays a significant role in the immune system's response to viral infections. It does not form a complex but aids in the synthesis of 2'-5'-linked oligoadenylates which activate RNase L leading to the degradation of viral RNA. By doing so OASL helps to restrict viral replication and propagation within the host organism strengthening the antiviral response.

Pathways

OASL is actively involved in the interferon signaling pathway and the innate immune response pathway. It works closely with other proteins such as RIG-I-like receptors which are essential for detecting viral RNA and triggering downstream signaling processes. These interactions highlight OASL's integral function in coordinating antiviral defense strategies within these pathways.

OASL has connections to viral infections and autoimmune disorders. During infections by viruses like hepatitis C OASL contributes to the host's defense by limiting viral replication. Additionally its involvement in autoimmune conditions such as systemic lupus erythematosus demonstrates its role in immune system regulation. In these contexts OASL associates with proteins like MAVS which facilitate innate immune signaling and modulate disease mechanisms.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 1 US: 1

Adherent/suspension

Adherent

Gender

Male

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com